Reuters logo
BRIEF-Alnylam initiates phase 2 clinical study of cemdisiran (ALN-CC5)
September 26, 2017 / 12:33 PM / 3 months ago

BRIEF-Alnylam initiates phase 2 clinical study of cemdisiran (ALN-CC5)

Sept 26 (Reuters) - Alnylam Pharmaceuticals Inc

* Alnylam initiates phase 2 clinical study of cemdisiran (ALN-CC5) in patients with atypical hemolytic-uremic syndrome (aHUS)

* Says ‍expects to report initial patient data in 2018​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below